xbibackto70s
Posted - 9 hours ago
$KNSA this co is a joke wtf f u markets
xbibackto70s
Posted - 14 hours ago
$KNSA adding more so undervalued
Jtree123
Posted - 18 hours ago
$KNSA JP Morgan raises price target to $30
xbibackto70s
Posted - 1 day ago
$KNSA adding
StockInvest_us
Posted - 1 day ago
Signal alert: $KNSA - PivotPoint bottom https://stockinvest.us/l/HzCNm85fFX
Thestocktraderhubzee
Posted - 04/25/24
WATCHLIST APR 25 2024..
$CFG Argus Research Maintains Buy on Citizens Financial Group, Raises Price Target to $39
$PII Citigroup Maintains Neutral on Polaris, Lowers Price Target to $96
$GILD HSBC Upgrades Gilead Sciences to Hold, Announces $69 Price Target
$KNSA Evercore ISI Group Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $30
$FCX Scotiabank Maintains Sector Outperform on Freeport-McMoRan, Lowers Price Target to $53
Iceberg99
Posted - 04/24/24
$KNSA $CRDL News Breaks
April 24, 2024
KNSA Kiniksa price target raised to $30 from $25 at Evercore ISIEvercore ISI analyst Liisa Bayko raised the firm's price target on Kiniksa to $30 from $25 and keeps an Outperform rating on the shares. The firm cites two reasons it is "lovin' KNSA," namely that lead asset Arcalyst accelerating in recurrent pericarditis and that the company will be cash flow positive this year and beyond. The firm, which notes that it got some additional color on abiprubart on the earnings call, adds that it will "remain in wait and see mode before assigning more value," noting that value for the asset currently represents $5 of its $30 price target on Kiniksa shares.
epsguid
Posted - 04/23/24
$KNSA reported a loss of $0.25, consensus was ($0.14) via @eWhispers #epsmiss http://eps.sh/d/knsa
DonCorleone77
Posted - 04/23/24
$KNSA Kiniksa sees FY24 ARCALYST product revenue $370M-$390M Kiniksa expects 2024 ARCALYST net product revenue of between $370 million and $390 million, compared to prior guidance of between $360 million and $380 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis.
Stock_Titan
Posted - 04/23/24
$KNSA Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
https://www.stocktitan.net/news/KNSA/kiniksa-pharmaceuticals-reports-first-quarter-2024-financial-results-mk3tmx42aqqv.html
Stock_Titan
Posted - 04/16/24
$KNSA Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
https://www.stocktitan.net/news/KNSA/kiniksa-pharmaceuticals-to-report-first-quarter-2024-financial-iuz5fqsbxijz.html
DasBrinkus
Posted - 04/12/24
@rconnersom685 @GatorMcKlusky @inB4theDillution @clownmarket Personally I think this is trading here for a couple of reasons. Not being FCF positive is the main culprit. Take a look at $KNSA and this ticker from end of 2021 to now. They got lean and licensed out the majority of their pipeline and still have good traction of revenue ramp since launch. We spent a lot of money with little to show for it on the pipeline Gali/FOP/9930/10013. Also our revenue recognition seems to be linear the last couple of years. CM and I differ here on this point but we keep it cordial. His belief and the company’s is that they will accelerate growth into the latter part of the decade. I tend to side with the analysts and ballpark their peak Orladeyo revenues lower. Lastly, there are some hurt feelings here. The pulled offering, share sells prior to bad news, and Baker just selling and admitting essentially they’ve been shorting this heavy for years
StockInvest_us
Posted - 04/09/24
Signal alert: $KNSA - Oversold Trend Short (Undervalued) https://stockinvest.us/l/cdIEuvKMoG
DasBrinkus
Posted - 04/08/24
$KNSA @RonIsWrong @AttorneysRealty Setup is starting to look intriguing. 200 day SMA and EMA coming into play but lots of macro data due this week. Last year ER was May 2, so perhaps a swing that lasts a couple of weeks or perhaps a decent time to begin scaling back in for long term accounts. Cash flow positive and no debt seems a relatively safe bet to make on a longer time frame.
Happy_Feet19
Posted - 04/06/24
$KNSA This looks like no big deal to shareholders. Any Concerns on the Chat? KNSA: Kiniksa Pharmaceuticals proposes redomiciliation from Bermuda to the United Kingdom (19.73) Kiniksa does not expect the Redomiciliation will have any material impact on its financial results. Kiniksa would continue be subject to the same reporting obligations with the U.S. Securities and Exchange Commission. New Kiniksa's Class A ordinary shares would be expected to continue to trade on the Nasdaq Global Select Market under the ticker symbol "KNSA". Full details of the proposed Redomiciliation, and the associated benefits and risks, will be provided to shareholders in a proxy statement with respect to a shareholders' meeting. If approved, the Company expects to complete the Redomiciliation in the second half of 2024.
xbibackto70s
Posted - 04/05/24
$KNSA added should be a hammer close today this is so undervalued
xbibackto70s
Posted - 04/03/24
$KNSA mgmt has done absolutely 0 for this stock in years! Patience leadership
RonIsWrong
Posted - 1 month ago
$KNSA Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart – Abiprubart Phase 2b trial in Sjogren’s Disease planned to initiate in 2H 2024 – – Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity – – Abiprubart development in Sjogren’s Disease fully funded through Phase 3 – Kiniksa expects to remain cash flow positive on an annual basis within its current operating plan, which includes advancement of abiprubart through Phase 3 development in Sjogren’s Disease.
RonIsWrong
Posted - 1 month ago
$KNSA
Stock_Titan
Posted - 1 month ago
$KNSA Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
https://www.stocktitan.net/news/KNSA/kiniksa-pharmaceuticals-announces-development-indication-for-fuc80cfrsc3t.html
RonIsWrong
Posted - 03/29/24
$KNSA On March 29, 2024, Kiniksa Pharmaceuticals, Ltd [...] announced that it intends to change the place of incorporation of Kiniksa’s principal holding company from Bermuda to the United Kingdom Kiniksa has determined that Bermuda is no longer the most desirable jurisdiction for Kiniksa’s principal holding company’s place of incorporation and believes that redomiciling Kiniksa’s principal holding company from Bermuda to a country with a more expansive tax treaty with the United States would be in the best interests of shareholders, employees and other stakeholders
Fastcapital
Posted - 03/28/24
$CRDL this stock is onto something can just sense it. Will be a major winner for me. Look at this statement from the company from the Orphan drug designation PR. "The FDA's decision was based on pre-clinical data combined with initial clinical data from the Company's MAvERIC-Pilot Phase II study," this definitely states that the results from the initial phase 2 data was impressive. There is only one FDA approved medicine for pericarditis and it is a way worse unhealthy and expensive medicine. Company is valued at $1,4B Company is $KNSA Their target revenue is way higher with lower cost also will be available in Europe.
First line treatment vs third line treatment 💰
This is major news. Here is the PR: https://finance.yahoo.com/news/cardiol-therapeutics-granted-orphan-drug-122700673.html
fda_tracker
Posted - 03/20/24
$KNSA Phase 2 trial w/est Mar completion date NCT05198310: https://www.clinicaltrials.gov/study/NCT05198310 Trial Tracker: https://www.fdatracker.com/trial-tracker/
xbibackto70s
Posted - 03/18/24
$KNSA added bunch
JHSSSS
Posted - 03/13/24
$KNSA These sales by the executives is foreshadowing. Take note and sell other than what you’re willing to ride for years.
InsiderPeek
Posted - 03/12/24
$KNSA CEO Patel Sanj K sold 65k shares for $1.4 millions (ownership down 28.6%) insiderpeek.com/company/KNSA
insiderbuyingselling
Posted - 03/11/24
$KNSA new insider selling: 65012 shares. http://insiderbuyingselling.com/?t=KNSA
Blueshadows
Posted - 03/11/24
$CRDL $KNSA
